TEVA Director Roberto Mignone Sells 367,600 Shares

What Happened Roberto Mignone, a director of Teva Pharmaceutical Industries Ltd. (TEVA), sold 367,600 ordinary shares in open-market transactions on Sept. 18, 2026. The sales generated approximately $14,356,802, at a weighted-average price of $39.06 per share (individual trade prices ranged from $38.68 to $39.38).

Key Details

• Transaction date: 2026-09-18 (reported on Form 4 filed 2026-09-22) — filing appears to be within the typical 2-business-day window.
• Transaction type/code: Sale (S); total shares sold: 367,600; weighted-average price: $39.06; total proceeds ≈ $14,356,802.
• Price range: trades executed between $38.68 and $39.38 (reporting person will provide per-trade breakdown upon request — F1).
• Ownership after transaction: The 367,600 shares were held of record by Swiftcurrent Master Fund Ltd. and were disposed. Mr. Mignone is manager of Bridger Management, LLC (the fund’s adviser) and was deemed to beneficially own the shares under Rule 16a-1(a)(1), but he disclaims direct beneficial ownership except for any indirect pecuniary interest (F2). The filing does not list additional personal holdings for Mr. Mignone.
• Notable footnotes: F1 (weighted average price and per-trade price range) and F2 (shares were held by an institutional fund; Mignone’s ownership is deemed under Rule 16 with a disclaimer).
• Timeliness: Filed 2026-09-22 for a 2026-09-18 trade — appears timely under Section 16 reporting rules.

Context This filing reports a sale of shares held by an institutional fund for which Mr. Mignone is the manager/adviser — such institutional disposals are often routine and do not necessarily indicate personal trading intent. As a sale, it is less informative about positive insider sentiment than a purchase would be; the filing is factual and does not state motivations.